Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells-Reference-Cited by-同舟云学术

Identification of a highly efficient dual type I/II FMS-like tyrosine kinase inhibitor that disrupts the growth of leukemic cells

Published:2021-11 Issue: Volume: Page:
ISSN:2451-9456
Container-title:Cell Chemical Biology
language:en
Short-container-title:Cell Chemical Biology

Author:

Beyer Mandy,Henninger Sven J.,Haehnel Patricia S.,Mustafa Al-Hassan M.,Gurdal Ece,Schubert Bastian,Christmann Markus,Sellmer Andreas^ORCID,Mahboobi Siavosh,Drube Sebastian,Sippl Wolfgang^ORCID,Kindler Thomas,Krämer Oliver H.

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology,Molecular Biology,Molecular Medicine,Biochemistry

Reference70 articles.

1. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib;Albers;Leukemia,2013

2. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions;Antar;Leukemia,2020

3. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L);Bagrintseva;Blood,2005

4. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases;Baska;Eur. J. Med. Chem.,2019

5. How to distinguish between the activity of HDAC1-3 and HDAC6 with western blot;Beyer;Methods Mol. Biol.,2017

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells;Biomedicine & Pharmacotherapy;2024-08

2. Targeting hematological malignancies with isoxazole derivatives;Drug Discovery Today;2024-08

3. Pharmacological degradation of ATR induces antiproliferative DNA replication stress in leukemic cells;Molecular Oncology;2024-03-22

4. FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review;Critical Reviews in Oncology/Hematology;2023-11

5. Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3;Leukemia;2023-09-21